Physician profile
Manuel E Babaian
NPI 1649374950
$5,842.63
in general payments reported to CMS, 2019-2025
20 companies · $915 in 2025
The $915 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $575 · 2021: $1,211 · 2022: $1,041 · 2023: $556 · 2024: $545 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,015.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,469.20 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,393.32 | 2019-2025 | Linzess, Viberzi, Mavyret |
| Madrigal Pharmaceuticals | $496.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $487.91 | 2019-2022 | |
| Redhill Biopharma INC. | $356.12 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $287.75 | 2021-2023 | |
| Cumberland Pharmaceuticals, INC. | $280.69 | 2020-2023 | Kristalose |
| Exact Sciences Corporation | $218.55 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $155.67 | 2023-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $145.93 | 2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $127.59 | 2019-2021 | |
| Gilead Sciences, INC. | $120.34 | 2020-2023 | Epclusa |
| Ironwood Pharmaceuticals, INC | $110.85 | 2020-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $66.49 | 2025 | Iqirvo |
| Ardelyx, INC. | $34.60 | 2025 | Ibsrela |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $30.08 | 2022-2024 | Inflation Device |
| Novo Nordisk INC | $19.83 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $15.06 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.64 | 2019 | |
| Allergan, INC. | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Babaian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.